 Desmopressin-induced improvement times chronic renal failure patients platelet serotonin ATP release Hemostatic defects life-threatening hemorrhagic episodes common occurrence chronic renal failure patient Hemorrhagic tendencies laboratory tests times identification specific hemostatic defect role dyscrasias studies factor VIII coagulant activity factor VIII antigen vWF Ag normal uremic renal failure patients bleeding times multimeric state von Willebrand factor normal patients bleeding times patients minutes post-infusion desmopressin DDAVP significant changes factor VIII/vWF properties blood cell counts coagulation factors post-DDAVP treatment significant increase platelet serotonin uptake ATP release DDAVP treatment results DDAVP platelet membrane ability DDAVP vasopressin-induced platelet aggregation dose- time-dependent fashion Perturbations movement storage serotonin release adenosine ATP platelets uremic individuals critical role times